Loading clinical trials...
Loading clinical trials...
This is a Phase 3, multicenter, open-label and roll-over study in participants who are 12 to \<24 months of age at initiation of Lumacaftor/Ivacaftor (LUM/IVA) treatment.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Vertex Pharmaceuticals Incorporated
NCT07102043 · Cystic Fibrosis Related Diabetes
NCT06616857 · Cystic Fibrosis (CF)
NCT05937815 · Cystic Fibrosis
NCT07148739 · Cystic Fibrosis (CF)
NCT02417740 · Cystic Fibrosis, Immunologic Deficiency Syndrome, and more
University of Alabama at Birmingham
Birmingham, Alabama
Arkansas Children's Hospital
Little Rock, Arkansas
Children's Hospital Colorado
Aurora, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions